/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Nucleate Podcast
  2. From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky
From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky

Nucleate Podcast · Oct 20, 2026

SciMed's Matias Serebrinsky on backing frontier brain health—from psychedelics to precision psychiatry—and why story and execution matter.

Scientific founders must combine deep expertise with ruthless execution.

Matias Serebrinsky borrows the OSS's Cold War ideal-spy test—'a PhD that can win a bar fight'—to describe SciMed Ventures' founder target. He wants technical depth plus ruthless execution speed, and says credentialism matters less than those traits. The phrase captures the dual requirement: scientific understanding and operator instinct.

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky thumbnail

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky

Nucleate Podcast·a month ago

Psychedelic bets trade technical risk for reimbursement risk.

SciMed chose to accept more market and regulatory risk in psychedelics because the clinical science looked strong, Matias says. He points to uncertainty over payer reimbursement and pharma acquisitions as the tradeoff for underwriting less technical risk. The FDA's openness, including breakthrough designations, made that bet feel more reasonable.

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky thumbnail

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky

Nucleate Podcast·a month ago

Non-hallucinogenic psychedelics may become best-in-class.

Matias expects classic psychedelics may reach approval first, but says best-in-class compounds may be non-hallucinogenic. He cites Gilgamesh's AbbVie-linked program and Delix's positive Phase 1b data as evidence for this newer generation. The thesis is that first-in-class does not stay best-in-class by default, and he is bullish on the category.

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky thumbnail

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky

Nucleate Podcast·a month ago

Closed-loop neurotech turns devices into multi-indication platforms.

Matias says old medical devices were single-indication assets, but brain-computer interfaces are becoming horizontal platforms. Miniaturization plus better algorithms enable closed-loop read-and-stimulate systems, and neurotech's circuit-level interface makes many psychiatric applications plausible. That shift is why he is excited about devices despite their historical reputation.

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky thumbnail

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky

Nucleate Podcast·a month ago

De-risk startups with faster indications before Alzheimer's.

Matias warns founders often chase huge indications like Alzheimer's without a fast way to test their hypothesis. He prefers plans that validate in smaller, biomarker-defined populations first, then expand once the company is de-risked. He frames validation as the core early startup job, especially until better surrogate endpoints exist.

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky thumbnail

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky

Nucleate Podcast·a month ago

Precision neuroscience is blocked by data and business models.

Matias says precision neuroscience is limited by messy, non-normalized data and by a missing business model. Wearables and other data exist, but few multidisciplinary teams turn them into a source of truth or deploy them with aligned incentives. He lists these practical gaps alongside the brain's underlying complexity.

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky thumbnail

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky

Nucleate Podcast·a month ago

RNA excitement centers on delivery, not just AI.

Matias says many hot biotech companies use AI without being AI-first; the harder problem is delivery. For RNA and oligo therapies, he highlights crossing the blood-brain barrier with brain shuttles and getting compounds inside the right cell. Those enabling technologies are where SciMed is seeing interesting companies.

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky thumbnail

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky

Nucleate Podcast·a month ago

NVIDIA work convinced him neuroscience was becoming tractable.

Matias says his time at NVIDIA gave him an insider view of AI progress—more compute, better data, better models—converging with neurobiology. That visibility helped convince him a venture fund focused on brain and mental health could work. He calls it one of the lucky breaks behind SciMed's launch.

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky thumbnail

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky

Nucleate Podcast·a month ago

Storytelling is an eternal founder skill, not just fundraising.

Matias says storytelling is not just for fundraising. Founders must sell constantly to A-plus hires, pharma partners, and public-market analysts, and they need to transfer genuine excitement rather than merely polish slides. He calls it a critical, permanent founder skill because every stakeholder has other options.

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky thumbnail

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky

Nucleate Podcast·a month ago

SciMed's podcast and workshops aim to inspire neuro founders.

Matias says SciMed's podcast and Future Neuro Founders workshop exist to inspire scientists to start companies. The podcast is also a selfish learning tool: he would keep recording even with one listener because he gains so much from the conversations. He calls the effort both selfless and extremely selfish.

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky thumbnail

From PlayStation to Psychedelics: A Brain Health VC's Pivot | Matias Serebrinsky

Nucleate Podcast·a month ago